OUR PRODUCT PIPELINE

IS ORGANIZED AROUND THREE THERAPY AREAS:

1. CHRONIC WOUNDS

Lead product: AUP-16

We have completed our Phase 1 clinical study in Diabetic Foot Ulcer (DFU) patients, and we are now moving to Phase 2. First for DFU, and then for Venous Ulcers and other non-healing wounds.

2. ONCOLOGY

Lead candidates: AUP-55 and AUP-65

We have obtained pre-clinical results in ovarian cancer and other secondary peritoneal carcinomatosis.

3. INFLAMMATION

Lead candidates: AUP-18 and AUP-20

Both are at the discovery stage.

Picture of Aurealis Therapeutics Pipeline

With our established platform, creating customized new products with desired 2-3 human therapeutic proteins can be done in only six weeks.

With our established platform, creating customized new products with desired 2-3 human therapeutic proteins can be done in only six weeks.

THE PROBLEM

No effective treatment that can hit multiple targets as one product.

We believe that when treating complex diseases like chronic inflammation and cancer, one needs to hit multiple targets to be disease-modifying. Very few companies or products can claim to truly target multiple biological targets. With our 4-in-1 technology, we can.

The wound healing process, for example, involves multiple steps: inflammation, proliferation, angiogenesis, and epithelialization. This process occurs naturally in normal circumstances. However, in chronic non-healing wounds, this process is impaired – wounds remain in the inflammation stage. To successfully restart wound healing in chronic non-healing wounds, it is essential to activate different biologic targets.

AUREALIS THERAPEUTICS 4-IN-1 PRODUCT AUP-16

Even though many different treatments exist today – traditional or moist wound dressings, negative pressure wound therapy, cell and tissue-based products, skin substitutes, and growth factors – most existing products only tackle one target with a single mode of action.

That is why we created Aurealis Therapeutics 4-in-1 platform.

OUR SOLUTION: aurealis therapeutics 4-in-1 platform

A synthetic biology, cell and gene therapy platform based on modified food-grade lactic acid bacteria. These bacteria are genetically modified to include 90 copies of a plasmid, allowing them to synthesize multiple human therapeutic proteins, acting as millions of bioreactors in the body.

We are the only company in the world to have genetically engineered bacteria expressing three human therapeutic proteins.

This novel cell and gene therapy platform is backed by pre-clinical and clinical results in wide-ranging applications from diabetic foot ulcers, other non-healing wounds, oncology and inflammatory diseases. 

A synthetic biology, cell and gene therapy platform based on modified food-grade lactic acid bacteria. These bacteria are genetically modified to include 90 copies of a plasmid, allowing them to synthesize multiple human therapeutic proteins, acting as millions of bioreactors in the body.

We are the only company in the world to have genetically engineered bacteria expressing three human therapeutic proteins.

This novel cell and gene therapy platform is backed by pre-clinical and clinical results in wide-ranging applications from diabetic foot ulcers, other non-healing wounds, oncology and inflammatory diseases. 

LEARN MORE ABOUT:

CHRONIC WOUNDS

AUP-16 is our lead clinical asset for chronic wounds.

ONCOLOGY

AUP-55 is our lead pre-clinical asset in oncology.